While reporting financial results for the fourth quarter on Friday, biopharmaceutical company ANI Pharmaceuticals, Inc. (ANIP) initiated its adjusted earnings for the full-year 2025, while raising annual revenue outlook. For fiscal 2025, the company now projects adjusted earnings in a range of $6.12 to $6.49 per share on net revenues between $756 million and $776 million, up from the prior revenue outlook between $739 million and $759 million.
https://www.nasdaq.com/articles/ani-pharma-raises-fy25-revenue-outlook-stock-8-update
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.